Genoptix Announces Participation at Lazard Capital Management 6th Annual Healthcare Conference
November 10 2009 - 10:52AM
PR Newswire (US)
CARLSBAD, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Genoptix, Inc.
(NASDAQ:GXDX), a specialized laboratory services provider, today
announced the Company's participation at the Lazard Capital
Management 6th Annual Healthcare Conference at The St. Regis Hotel
in New York City on November 17-18, 2009. Genoptix's EVP and CFO,
Doug Schuling, will present at the conference on Tuesday, November
17, 2009 beginning at approximately 11:25 a.m. EST. He will provide
an overview of the Company's specialized diagnostic laboratory
services business, growth strategies and financial performance. The
presentation is expected to last approximately 30 minutes,
including a Q&A session, which will be web cast live and made
accessible through the "Investors" section of the Genoptix website
at http://www.genoptix.com/. Those who would like to listen to the
presentation should go to this site at least 15 minutes prior to
the event to register, download and install any necessary software.
A replay will also be available for 30 days following the initial
presentation web cast. About Genoptix, Inc. Genoptix is a leading
specialized laboratory service provider focused on delivering
personalized and comprehensive diagnostic services to its physician
customers, community-based hematologists and oncologists. On the
forefront of personalized diagnostic services, Genoptix's highly
trained group of hematopathologists utilize sophisticated
technology to provide integrated testing and actionable diagnostic
reports. Its diagnostic services are designed to optimize the care
of patients suffering from hematomalignancies, or cancers of the
blood and bone marrow, including leukemia and lymphoma. Founded in
1999, Genoptix completed its initial public offering in November
2007 and is headquartered in Carlsbad, California. For more
information, please visit http://www.genoptix.com/. Forward-Looking
Statements This press release contains forward-looking statements
that are subject to risks and uncertainties that could cause actual
results to differ materially from those set forth in the
forward-looking statements. Genoptix disclaims, however, any intent
or obligation to update these forward-looking statements.
DATASOURCE: Genoptix, Inc. CONTACT: Marcy Graham, Sr. Director,
Investor Relations of Genoptix, Inc., +1-760-930-7150, ; or Sarah
Thailing, Principal of Wordanista, +1-619-994-1895, , for Genoptix,
Inc. Web Site: http://www.genoptix.com/
Copyright